Source comparison
BPC-157 Research Intermediate Strategies: Protocol Comparison
Split-Dose Protocol (3× daily) Sustained VEGF receptor occupancy 200–250mcg every 6–8 hours instead of 300–500mcg twice daily 25–35% improvement in sustained angiogenic signaling Optimal for tendon/ligament repair where continuous angiogenesis determines outco
This comparison does not assign a generated winner or score.
- Split-Dose Protocol (3× daily)
- Sustained VEGF receptor occupancy
- 200–250mcg every 6–8 hours instead of 300–500mcg twice daily
- 25–35% improvement in sustained angiogenic signaling
- Optimal for tendon/ligament repair where continuous angiogenesis determines outcome
- Front-Loaded Acute Dosing
- Acute-phase VEGF receptor saturation
- 500–750mcg twice daily days 1–7, then 250–350mcg twice daily
- 40% faster initial capillary formation in animal models
- Best for traumatic injuries with defined acute phase
- Localized Injection (peri-injury)
- Concentration gradient at injury site
- Inject within 2–3cm of injury instead of distant subcutaneous
- 40% higher local collagen deposition vs systemic injection
- Critical for localized tissue repair; unnecessary for systemic effects
- BPC-157 + TB-500 Stack
- Angiogenesis + cellular migration
- BPC-157 twice daily + TB-500 once daily
- 60% faster wound closure vs monotherapy
- Gold standard for comprehensive soft tissue repair
- BPC-157 + GHK-Cu Stack
- Angiogenesis + collagen remodeling
- BPC-157 weeks 1–6 + GHK-Cu weeks 3–8
- 70% improvement in tensile strength of healed tissue
- Addresses both repair and remodeling phases sequentially